Chiral Se@CeO₂ superparticles for ameliorating Parkinson's disease

Area of Science:

• Nanotechnology and Materials Science
• Biomedical Engineering
• Neuroscience

Background:

• Neurodegenerative diseases like Parkinson's disease (PD) are characterized by oxidative stress and protein aggregation.
• Current treatments for PD are limited, highlighting the need for novel therapeutic strategies.
• Cerium oxide nanoparticles (CeO2 NPs) are known for their antioxidant properties, but their efficacy can be enhanced.

Purpose of the Study:

• To synthesize novel chiral selenium-cerium oxide superparticles (Se@CeO2) using D-/L-cysteine as chiral ligands.
• To investigate the enzyme activities and reactive oxygen species (ROS) scavenging capabilities of these chiral superparticles.
• To evaluate the therapeutic potential of chiral Se@CeO2 superparticles in a mouse model of Parkinson's disease.

Main Methods:

• Preparation of chiral D-/L-type Se@CeO2 superparticles (SPs) utilizing D-/L-cysteine.
• Assay of enzyme activities including peroxidase (POD), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx).
• Evaluation of ROS scavenging ability in a PD-like cell model and assessment of α-synuclein levels in PD mouse models.

Main Results:

• Chiral Se@CeO2 SPs exhibited significantly enhanced enzyme activities compared to a mixture of Se NPs and CeO2 NPs, with synergistic effects observed.
• Chiral L-SPs demonstrated superior ROS scavenging capacity in a PD-like cell model compared to D-SPs.
• Treatment with L-SPs reduced α-synuclein levels by 70.7% in the cerebrospinal fluid of PD mice within two weeks, alleviating neurodegeneration.

Conclusions:

• Chiral Se@CeO2 superparticles possess ultra-high enzyme activities and potent ROS scavenging abilities, attributed to the synergistic interaction between Se and CeO2.
• The study demonstrates the significant therapeutic potential of chiral L-Se@CeO2 superparticles in alleviating neurodegeneration in a Parkinson's disease mouse model.
• These findings suggest that chiral Se@CeO2 superparticles could be a promising candidate for the clinical treatment of neurodegenerative diseases.